NCOR2 and lymphoma: From the first defined decoy peptide mimicking the SMRT peptide that interacts with BCL6 and inhibits BCL6/SMRT PPI [168], other peptidomimetics were developed with interesting cellular activities and in vivo anti-lymphoma potencies as L-BPI or PR-BPI [169], F1324 [170] or the cyclo-CIYYCV [171].